Clinical trials: Immunization; Infection
HIV Infections
Autologous Dendritic Cell Vaccine in HIV1 Infection
This study aims to look at the safety and tolerability of immunization with dendritic cell vaccine prepared using the patient's own cells and virus.
- Trial name
- NCT00510497
- Testing
- Autologous HIV-1 ApB DC Vaccine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Sharon Riddler
HIV Exposure, HIV Infection
Early Versus Delayed BCG Vaccination of HIV-exposed Infants
In sub-Saharan Africa (SSA), more than 300,000 babies with HIV die each year. HIV-infected children develop AIDS and die faster in SSA than those in developed countries.
- Trial name
- NCT02062580
- Testing
- BCG
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- University of Cape Town
HIV Infection, Hepatitis B
B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B
The purpose of this study was to evaluate response to and safety of the HBV vaccine HEPLISAV-B in two study populations of people living with HIV: prior HBV vaccine recipients who are deemed non-responders and individuals who are…
- Trial name
- BEe-HIVe (NCT04193189)
- Testing
- HEPLISAV-B, ENGERIX-B
- Where
- 41 sites in United States, Botswana and 8 more
- Volunteers
- 638 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diphtheria
A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.
The purpose of this study is to assess the safety of RefortrixTM (Tdap) when administered during pregnancy in a maternal immunization program in Brazil.
- Trial name
- NCT02757950
- Testing
- Combined diphtheria, tetanus and tricomponent acellular pertussis vaccine [Refortrix (Tdap)]
- Where
- Brazil
- Volunteers
- 2,462 people
- Sponsor
- GlaxoSmithKline
COVID-19, COVID-19 Immunisation
Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)
This is a phase I, open-label, dose-ranging clinical trial in males and non-pregnant females, starting at 18 years of age, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT04283461
- Testing
- mRNA-1273
- Where
- 3 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pneumococcal Infections, COPD
Immunization To Prevent Acute COPD Exacerbations
Prospective multicenter observational study, to evaluate the impact of routine clinical practice vaccination with PCV13 on the reduction of the risk of moderate/severe COPD exacerbations
- Trial name
- NCT03276754
- Where
- 11 sites in Spain
- Volunteers
- 530 people
- Sponsor
- Pfizer
Influenza, Vaccine Hesitancy
Precision Vaccine Promotion in Underserved Populations
Previous studies have shown that low-cost, behavioral nudges through texting can increase influenza vaccination uptake compared to usual care.
- Trial name
- NCT05537441
- Testing
- Text messaging
- Where
- United States
- Volunteers
- 228,831 people
- Sponsor
- University of Southern California
Orthomyxoviridae Infection, Influenza
Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects
As a result of the safety and immunogenicity data generated from earlier dose-ranging studies, the present formulation has been selected for further development in the elderly.
- Conditions
- Orthomyxoviridae Infection, Influenza, Myxovirus Infection
- Trial name
- NCT00388583
- Testing
- Split, Inactivated, Trivalent Influenza Vaccine
- Where
- 17 sites in United States
- Volunteers
- 817 people, healthy volunteers welcome
- Sponsor
- Sanofi
Infections, Streptococcal, Streptococcus Pneumoniae Vaccines
Primary Vaccination Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Vietnam
The purpose of the study is to evaluate the safety and reactogenicity of Synflorix™ (GSK 1024850A) given as a 3-dose primary immunization course when co-administered with Infanrix hexa™ vaccine at 2, 3 and 4 months of age in…
- Trial name
- NCT01153841
- Testing
- Synflorix™( GSK1024850A), Infanrix hexa™
- Where
- Vietnam
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cardiovascular Diseases, Atrial Fibrillation
A Digital Flu Intervention for People With Cardiovascular Conditions
A 6-month prospective, digital randomized controlled trial targeting approximately 49,000 individuals to evaluate the effectiveness of an influenza vaccination intervention during influenza season for people with cardiovascular…
- Conditions
- Cardiovascular Diseases, Atrial Fibrillation, Abnormal Heart Rhythms, Cardiac Arrest
- Trial name
- CardioFlu (NCT04584645)
- Testing
- Targeted digital intervention
- Where
- United States
- Volunteers
- 49,138 people
- Sponsor
- Evidation Health
Prevention of COVID-19
Assessing Immune Response of Different COVID-19 Vaccines in Older Adults
This is a randomised controlled, adaptive, multicentre Phase II protocol evaluating different booster strategies in individuals aged 75 years and older already vaccinated against SARS-CoV-2.
- Trial name
- EU-COVAT-1 (NCT05160766)
- Testing
- Comirnaty (BTN162b2), Spikevax (mRNA-1273)
- Where
- 9 sites in Germany, Lithuania and 2 more
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Oliver Cornely, MD
Herpes Zoster
Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects
Based on the results of a previous clinical PhaseI/II study, GSK1437173A is the lead GSK candidate Herpes Zoster (HZ) vaccine to prevent episodes of HZ (shingles).
- Trial name
- NCT00434577
- Testing
- Herpes Zoster vaccine GSK1437173A Low Dose, Herpes Zoster vaccine GSK1437173A Medium Dose, Herpes Zoster vaccine GSK1437173A High Dose
- Where
- 11 sites in Czechia, Germany and 2 more
- Volunteers
- 715 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Aging
Beta-glucan and Immune Response to Influenza Vaccine
This trial in healthy adults will determine the effects of beta-glucan, a dietary fiber supplement isolated from baker's yeast, on immune response to the influenza vaccine.
- Trial name
- M-Unity (NCT05074303)
- Testing
- Influenza Vaccine, Beta-glucan
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- University of Florida
Influenza
Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents
The present study is the first study designed to evaluate safety, tolerability and immunogenicity of the cell culture-derived influenza vaccine in healthy children and adolescents aged 3 to 17 years.
- Trial name
- NCT00645411
- Testing
- Cell culture-derived influenza subunit vaccine (cTIV), Egg derived influenza subunit vaccine (eTIV)
- Where
- 60 sites in United States, Croatia and 5 more
- Volunteers
- 3,604 people, healthy volunteers welcome
- Sponsor
- Novartis
Infections, Streptococcal, Streptococcus Pneumoniae
Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™
The aim of this study is to assess the immune response, safety and reactogenicity following administration of an additional dose of a pneumococcal conjugate vaccine at approximately 4 years of age in children previously…
- Trial name
- NCT00907777
- Testing
- Pneumococcal conjugate vaccine GSK 1024850A, Pneumococcal conjugate vaccine Prevenar™ (Wyeth Lederle's)
- Where
- 17 sites in Germany
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Influenza Immunisation
Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination
This was a Phase IV open label and single arm study, with the aim of enrolling up to 55 healthy males and non-pregnant females in a single site, age 18-49 years old, inclusive.
- Trial name
- NCT02485639
- Testing
- Influenza Virus Vaccine Inactivated
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infections, Streptococcal
Safety & Immunogenicity of Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First Vaccination
This study will assess the safety, reactogenicity and immunogenicity of different formulations of GSK Biologicals' pneumococcal vaccine 2189242A when administered alone or in combination with the 10-valent pneumococcal conjugate…
- Trial name
- NCT00985751
- Testing
- Pneumococcal vaccine GSK2189242A (formulation 1), Pneumococcal vaccine GSK2189242A (formulation 2), Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 3)
- Where
- 10 sites in Czechia
- Volunteers
- 257 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningitis, Meningococcal
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants
This study will evaluate the safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine when administered with routine infant vaccinations to healthy infants.
- Trial name
- NCT00474526
- Testing
- Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib
- Where
- 63 sites in United States, Argentina and 1 more
- Volunteers
- 4,545 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Haemophilus Influenzae Type b, Neisseria Meningitidis
3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age
This study evaluated the safety and immunogenicity of 3 formulations of Hib-MenCY-TT vaccine and 1 formulation of Hib-MenC-TT vaccine compared to a control group receiving licensed meningococcal serogroup C conjugate vaccine…
- Trial name
- NCT00129116
- Testing
- Hib-MenCY-TT vaccine, Hib-MenC-TT vaccine, Menjugate ®
- Where
- 26 sites in Belgium, Germany
- Volunteers
- 388 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in adults ≥ 65 years of age with and without Zostavax® vaccination at least 5 years earlier.
- Trial name
- NCT02581410
- Testing
- GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
- Where
- 32 sites in United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline